Increased levels of the soluble form of uPAR (suPAR) were reported in plasma from patients with AML, in particular in patients with residual disease after chemotherapy; suPAR levels correlated with the number of circulating tumor cells [36,37]. Here, PLAUR is linked to acute myeloid leukemia.